Pierre Fabre Ltd

Pierre Fabre Ltd is the British subsidiary of the French pharmaceutical and dermo-cosmetics group, the second-largest private pharmaceutical company in France. The UK pharmaceutical portfolio focuses on oncology, including Braftovi (encorafenib) and Mektovi (binimetinib) for BRAF-mutant melanoma, Navelbine (vinorelbine) for lung and breast cancer, and Nerlynx (neratinib) for HER2-positive breast cancer. The group also encompasses dermo-cosmetic brands including Avène, Ducray, René Furterer, A-Derma, and Klorane.